Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Meningitis Pipeline Drugs Market Report Overview

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life-threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening.

The meningitis pipeline products market research report provides comprehensive information on the therapeutics under development for meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for meningitis and features dormant and discontinued projects.

Meningitis Pipeline Products Market Segmentation by Targets

The key targets in the meningitis pipeline products market are ergosterol, GPI anchored wall transfer protein 1, chitin synthase, glycerol 3 phosphate oxidase, lanosterol 14 alpha demethylase, meningococcal capsular polysaccharide antigen, and thymidylate synthase. Ergosterol and GPI anchored wall transfer protein 1 are the leading targets in the meningitis pipeline drugs market.

Meningitis Pipeline Products Market Analysis by Targets

Meningitis Pipeline Products Market Analysis by TargetsFor more target insights into the meningitis pipeline products market, download a free report sample

Meningitis Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the meningitis pipeline products market are ergosterol inhibitor, GPI anchored wall transfer protein 1 inhibitor, chitin synthase inhibitor, lanosterol 14 alpha demethylase inhibitor, and thymidylate synthase inhibitor. Ergosterol inhibitor and GPI anchored wall transfer protein 1 inhibitor are the leading MoAs in the pipeline market.

Meningitis Pipeline Products Market Analysis by Mechanisms of Action

Meningitis Pipeline Products Market Analysis by Mechanisms of ActionFor more MoA insights into the meningitis pipeline products market, download a free report sample

Meningitis Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the meningitis pipeline products market are intramuscular, oral, intravenous, and subcutaneous. Intramuscular accounted for the highest number of meningitis drugs in development in terms of RoA in 2022.

Meningitis Pipeline Products Market Analysis by Routes of Administration

Meningitis Pipeline Products Market Analysis by Routes of AdministrationFor more RoA insights into the meningitis pipeline products market, download a free report sample

Meningitis Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the meningitis pipeline products market are conjugate vaccine, small molecule, vaccine, inactivated vaccine, subunit vaccine, and toxoid vaccine. The conjugate vaccine is the leading molecule type in the meningitis pipeline drugs market.

Meningitis Pipeline Products Market Analysis by Molecule Types

Meningitis Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the meningitis pipeline products market, download a free report sample

Meningitis Pipeline Products Market - Competitive Landscape

Some of the leading companies in the meningitis pipeline products market are Chengdu Olymvax Biopharmaceuticals Inc, Chongqing Zhifei Biological Products Co Ltd, Matinas BioPharma Holdings Inc, CanSino Biologics Inc, Jiangsu Kunli Biopharmaceutical Co Ltd, LG Chem Ltd, Liaoning Cheng Da Biotechnology Co Ltd, and Linnaeus Bioscience Inc among others. Chengdu Olymvax Biopharmaceuticals Inc is among the leading companies in the meningitis pipeline products market in 2022.

Meningitis Pipeline Products Market Analysis by Companies

Meningitis Pipeline Products Market Analysis by CompaniesTo know more about the leading meningitis pipeline products market players, download a free report sample

Meningitis Pipeline Products Market Overview

Key Targets Ergosterol, GPI Anchored Wall Transfer Protein 1, Chitin Synthase, Glycerol 3 Phosphate Oxidase, Lanosterol 14 Alpha Demethylase, Meningococcal Capsular Polysaccharide Antigen, and Thymidylate Synthase
Key MoA Ergosterol Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, Chitin Synthase Inhibitor, Lanosterol 14 Alpha Demethylase Inhibitor, and Thymidylate Synthase Inhibitor
Key RoA Intramuscular, Oral, Intravenous, and Subcutaneous
Key Molecule Type Conjugate Vaccine, Small Molecule, Vaccine, Inactivated Vaccine, Subunit Vaccine, and Toxoid Vaccine
Leading Companies Chengdu Olymvax Biopharmaceuticals Inc, Chongqing Zhifei Biological Products Co Ltd, Matinas BioPharma Holdings Inc, CanSino Biologics Inc, Jiangsu Kunli Biopharmaceutical Co Ltd, LG Chem Ltd, Liaoning Cheng Da Biotechnology Co Ltd, and Linnaeus Bioscience Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of meningitis.
  • The pipeline guide reviews pipeline therapeutics for meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in meningitis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates meningitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for meningitis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for meningitis.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the meningitis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

CanSino Biologics Inc
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Jiangsu Kunli Biopharmaceutical Co Ltd
LG Chem Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Pfizer Inc
Serum Institute of India Pvt Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Meningitis – Overview

Meningitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Meningitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meningitis – Companies Involved in Therapeutics Development

CanSino Biologics Inc

Chengdu Olymvax Biopharmaceuticals Inc

Chongqing Zhifei Biological Products Co Ltd

Jiangsu Kunli Biopharmaceutical Co Ltd

LG Chem Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Linnaeus Bioscience Inc

Matinas BioPharma Holdings Inc

Mycovia Pharmaceuticals Inc

Pfizer Inc

Serum Institute of India Pvt Ltd

TGV Therapeutics

Yisheng Biopharma Co Ltd

Meningitis – Drug Profiles

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine – Drug Profile

Product Description

Mechanism Of Action

(Haemophilus influenzae type b + rotavirus) vaccine – Drug Profile

Product Description

Mechanism Of Action

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

amphotericin B – Drug Profile

Product Description

Mechanism Of Action

APX-2039 – Drug Profile

Product Description

Mechanism Of Action

CSB-015 – Drug Profile

Product Description

Mechanism Of Action

flucytosine – Drug Profile

Product Description

Mechanism Of Action

Haemophilus influenzae B vaccine – Drug Profile

Product Description

Mechanism Of Action

LBVD – Drug Profile

Product Description

Mechanism Of Action

meningitis vaccine – Drug Profile

Product Description

Mechanism Of Action

meningitis vaccine – Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A and C] vaccine – Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A, C, W135, X, Y] vaccine – Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A, C] vaccine – Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A] vaccine – Drug Profile

Product Description

Mechanism Of Action

MYC-053 – Drug Profile

Product Description

Mechanism Of Action

pneumococcal (13-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

pneumococcal [serotype 4, 6A] vaccine – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Cryptococcal Meningitis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis – Drug Profile

Product Description

Mechanism Of Action

VT-1598 – Drug Profile

Product Description

Mechanism Of Action

Meningitis – Dormant Projects

Meningitis – Discontinued Products

Meningitis – Product Development Milestones

Featured News & Press Releases

Oct 23, 2022: Matinas BioPharma to present new MAT2203 (oral amphotericin B) data during IDWeek 2022

Oct 21, 2022: Matinas BioPharma announces positive interim data from the phase 2 EnACT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding primary endpoint threshold; patient survival in all-oral cohort 4 regimen currently 90%

Oct 19, 2022: Matinas BioPharma announces Infectious Diseases Society of America (IDSA) has selected the EnACT phase 2 trial abstract of MAT2203 as its outstanding abstract and IDSA awardee for IDWeek 2022

Dec 16, 2021: Matinas BioPharma announces unanimous DSMB approval to progress into fourth and final cohort of patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Sep 13, 2021: Matinas BioPharma announces positive data in the ongoing EnACT trial of MAT2203 (Oral Amphotericin B) for the treatment of cryptococcal meningitis, exceeding the prespecified primary endpoint threshold

Aug 16, 2021: Matinas BioPharma announces issuance of U.S. patent protecting MAT2203 to treat or prevent cryptococcus infections

Oct 19, 2020: Matinas BioPharma announces unanimous DSMB approval to progress into second cohort of patients in the EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Aug 20, 2020: Matinas BioPharma announces publication of results from phase 1 portion of the EnACT study investigating safety and tolerability of MAT2203

Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis

Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis

Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational

May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio

May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Meningitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Meningitis – Pipeline by CanSino Biologics Inc, 2022

Meningitis – Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022

Meningitis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022

Meningitis – Pipeline by Jiangsu Kunli Biopharmaceutical Co Ltd, 2022

Meningitis – Pipeline by LG Chem Ltd, 2022

Meningitis – Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022

Meningitis – Pipeline by Linnaeus Bioscience Inc, 2022

Meningitis – Pipeline by Matinas BioPharma Holdings Inc, 2022

Meningitis – Pipeline by Mycovia Pharmaceuticals Inc, 2022

Meningitis – Pipeline by Pfizer Inc, 2022

Meningitis – Pipeline by Serum Institute of India Pvt Ltd, 2022

Meningitis – Pipeline by TGV Therapeutics, 2022

Meningitis – Pipeline by Yisheng Biopharma Co Ltd, 2022

Meningitis – Dormant Projects, 2022

Meningitis – Dormant Projects, 2022 (Contd..1)

Meningitis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Meningitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.